FTC releases pay-for-delay study

The US Federal Trade Commission yesterday published a study showing that the lack of access to generic drugs caused by reverse settlement payments in the pharmaceutical industry could cost US consumers as much as US$35 billion over 10 years.

Purchase an approved for publication custom PDF below.

An official PDF provides excellent marketing opportunities, enabling you to post the article online, make reprints and distribute under the GCR brand.

• $200 (USD)
Add Amount: 1 2 3 4 5 6 7 8 9 10
• Add to Basket